NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director.

NanoSyrinx, an emerging biotechnology company developing new therapeutic modalities for Cell & Gene editing, announced the closing of a Pre-Seed financing led by M Ventures, the corporate venture capital arm of Merck. BioCity (Nottingham, United Kingdom) and UK Innovation & Science Seed Fund also participated in the financing.

New study published on rapid test for Coronavirus being developed by University of Warwick demonstrates detection using a model virus rather than just proteins. The diagnostic tool will function without any need for training or complex infrastructure, looking like a ‘pregnancy test’. The team are seeking philanthropic or investment partners to develop and take forward this new technology

The Universities of Birmingham and Warwick have created a new spinout company, 4D Medicine Ltd, to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffolds to help patients recover from major medical procedures more quickly.

The work being done at University of Warwick, in collaboration with Iceni Diagnostics, around developing a new approach to rapid coronavirus diagnostics has been featured on the BBC. On Thursday 25 June, BBC Midlands interviewed Professor Gibson and members of his team - a feature on this can be read on the BBC News web pages. You can also see the news report video here.

Coronavirus diagnostics currently require centralised facilities and collection/distribution of swabs and results are ‘next day’. A new diagnostic tool being developed by the University of Warwick and its partner Iceni Diagnostics may allow on-the-spot detection of Coronavirus infection, without facilities using a simple disposal device.

Humane Technologies Limited (HTL) has announced that it has successfully developed a prototype for the next generation of its microbial growth measurement device, the MicrobeMeter.

A new cryoprotectant polymer that dramatically improves the freezing of cells, has been discovered by researchers at the University of Warwick. The new polymers can reduce the amount of organic solvent required in cryopreservation (freezing cells) as well as giving more and healthier cells after thawing. Findings may help reduce cost and improve distribution of cells for cell-based therapies, diagnostics and research

Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment from Mercia Technologies PLC.

Founded in 2007 with support from Warwick Ventures and the University of Warwick, Base4 has just closed a £5 million funding round, the company's largest to date. The funds will be used to expand the current team and increase lab space, facilitating the continued fast-paced development and automation of its technology.